Skip Navigation

Neuro-Oncology 2006 8(3):280-283; doi:10.1215/15228517-2006-003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Noronha, V.
Right arrow Articles by Henson, J. W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Noronha, V.
Right arrow Articles by Henson, J. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Society for Neuro-Oncology

Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature1

Vanita Noronha, Nancy Berliner, Karen K. Ballen, Jill Lacy, Jean Kracher, Joachim Baehring and John W. Henson2

Division of Medical Oncology, Department of Medicine (V.N., N.B., J.L.) and Yale Brain Tumor Center, Departments of Neurology and Neurosurgery (J.B.), Yale University School of Medicine, New Haven, CT 06510; Division of Hematology and Oncology, Department of Medicine (K.K.B.) and Pappas Center for Neuro-Oncology (J.K., J.W.H.), Massachusetts General Hospital, Boston, MA 02114; and Harvard Medical School, Boston, MA 02115 (K.K.B., J.W.H.); USA

2 Address correspondence to John W. Henson, Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Yawkey 9 East, Fruit Street, Boston, MA 02114 (henson{at}helix.mgh.harvard.edu).


  Abstract

The emergence of temozolomide as an effective alkylating agent with little acute toxicity or cumulative myelosuppression has led to protracted courses of chemotherapy for many patients with gliomas. Secondary, or treatment-related, myelodysplasia (t-MDS) and acute myelogenous leukemia (t-AML) are life-threatening complications of alkylating chemotherapy and have been reported in patients with primary brain tumors. We describe a case of temozolomide-related t-MDS/AML and discuss the clinical features of this condition. Administration of an alkylating agent in patient populations with long median survivals must be undertaken with an understanding of the potential for this treatment complication.

Keywords: brain neoplasm, glioblastoma, myelodysplastic syndrome, recurrent glioma, secondary leukemia, secondary myelodysplastic syndrome, temozolomide, treatment complication

Received December 4, 2005; Accepted January 19, 2005


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Neuro OncologyHome page
T. S. Armstrong, Y. Cao, M. E. Scheurer, E. Vera-Bolanos, R. Manning, M. F. Okcu, M. Bondy, R. Zhou, and M. R. Gilbert
Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors
Neuro Oncology, December 1, 2009; 11(6): 825 - 832.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
S. J. Kim, T. S. Park, S. T. Lee, J. Song, B. Suh, S. H. Kim, S. J. Jang, C. H. Lee, and J. R. Choi
Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia after Treatment with Temozolomide in a Patient with Glioblastoma Multiforme
Ann. Clin. Lab. Sci., January 1, 2009; 39(4): 392 - 398.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Neyns, S. Cordera, E. Joosens, and P. Nader
Non-Hodgkin's Lymphoma in Patients With Glioma Treated With Temozolomide
J. Clin. Oncol., September 20, 2008; 26(27): 4518 - 4519.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.